A predictive model for prostate cancer incorporating PSA molecular forms and age | Scientific Reports
Characterizing Prostate-Specific Antigen Levels at Death in Patients with Metastatic Castration-Resistant Prostate Cancer: Are We Underutilizing Imaging? - Clinical Genitourinary Cancer
PSA‐alpha‐2‐macroglobulin complex is enzymatically active in the serum of patients with advanced prostate cancer and can degrade circulating peptide hormones - Kostova - 2018 - The Prostate - Wiley Online Library
Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter | NEJM
Frontiers | Label-Free Determination of PSA and Free PSA Using MA-SERS
Detection Performance of the Constructed PSA ECL Immunosensor (A)... | Download Scientific Diagram
a LSV responses at various concentrations of PSA (0.5, 5, 25, 100, 200,... | Download Scientific Diagram
PSA Testing for the Pretreatment Staging and Posttreatment Management of Prostate Cancer - American Urological Association
Detection Rate of Prostate Specific Membrane Antigen Tracers for Positron Emission Tomography/Computerized Tomography in Prostate Cancer Biochemical Recurrence: A Systematic Review and Network Meta-Analysis | Journal of Urology
Usefulness of the prostate health index in predicting the presence and aggressiveness of prostate cancer among Korean men: a prospective observational study | BMC Urology | Full Text
Prediction of metastatic prostate cancer by prostate-specific antigen in combination with T stage and Gleason Grade: Nationwide, population-based register study | PLOS ONE
Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study | BMJ Open
Prostate Specific Antigen (PSA) Test, Results, Levels & Ranges
PSA Testing | ZERO Prostate Cancer
Optimal Timing of Cabazitaxel Introduction for Japanese Patients With Metastatic Castration-resistant Prostate Cancer | Anticancer Research
![ECL obtained at 0.95 V vs. SCE with a [PSA] range of 0.4-5 ng mL À1 in... | Download Scientific Diagram](https://www.researchgate.net/publication/26730405/figure/fig1/AS:601688507424781@1520465127389/ECL-obtained-at-095-V-vs-SCE-with-a-PSA-range-of-04-5-ng-mL-A1-in-the-presence-of.png "ECL obtained at 0.95 V vs. SCE with a [PSA] range of 0.4-5 ng mL À1 in... | Download Scientific Diagram")
ECL obtained at 0.95 V vs. SCE with a [PSA] range of 0.4-5 ng mL À1 in... | Download Scientific Diagram
Pre-treatment prostate-specific antigen records in risk evaluation of prostate cancer
Normalization of prostate specific antigen in patients treated with intensity modulated radiotherapy for clinically localized prostate cancer | Radiation Oncology | Full Text
Detection Rate and Localization of Prostate Cancer Recurrence Using 68Ga-PSMA-11 PET/MRI in Patients with Low PSA Values ≤ 0.5 ng/mL | Journal of Nuclear Medicine
